Servier Maroc

What Servier Maroc does

Servier Maroc is a wholly-owned Moroccan pharmaceutical subsidiary of Servier Group, a foundation-governed French pharmaceutical company headquartered in Suresnes, France. Formally established at the end of 1996 after Servier's commercial presence in Morocco dating to the early 1970s, the entity operates as a société anonyme registered in Casablanca with share capital of 70,800,000 dirhams. The subsidiary markets a portfolio of 23 pharmaceutical products across four therapeutic areas (oncology, cardio-metabolism, neurosciences, and immuno-inflammation), including flagship brands such as Coversyl, Diamicron, Daflon, Lonsurf, and ONIVYDE. End customers are Moroccan patients (more than 600,000 treated daily) reached exclusively through authorized pharmacies, with field medical representatives engaging cardiologists, oncologists, and general practitioners through traditional pharmaceutical detailing.

The Nouasseur production site, built in 2003 with an initial 60 million dirham investment and certified by ANSM/France since 2006, manufactures dry dosage forms at a capacity of 8 million boxes per year and supplies over 95% of medications sold in Morocco by the company. The facility exports 40% of its output to 11 African countries and France and operates a Data Matrix serialization system (3.5 million dirham investment, 2019) to meet the EU Falsified Medicines Directive. Manufacturing services are also provided on a contract basis to European laboratories including Biogaran, demonstrating European-grade quality compliance at a Moroccan cost base. Complementary to pharmaceutical products, Servier Maroc deploys digital health assets (Tension Diali/My BP Control app, Cardiological educational tool, Biblioclick Family PubMed tool, and the Servier Medical Art image database) targeting adherence and physician engagement.

Servier Maroc operates under a traditional pharma go-to-market: branded and generic medications are sold through authorized pharmacies on a prescription-driven basis, with no direct-to-consumer internet sales. Revenue streams are diversified across domestic princeps (brand-name) sales, generic medications, and contract manufacturing/export. Governance by the Servier Group's non-profit foundation insulates the subsidiary from public market pressures and dividend distribution, enabling reinvestment into R&D (20%+ of group princeps revenue) and capacity expansion. Florent Darchez serves as Director General since September 1, 2021.

Name

Servier Maroc

Legal name

LES LABORATOIRES SERVIER

Website

https://servier.ma

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

51–100 employees

Short description

Servier Maroc is a Moroccan pharmaceutical subsidiary of foundation-governed Servier Group, manufacturing and distributing 23 branded medications across oncology, cardio-metabolism, neurosciences, and immuno-inflammation, with a GMP-certified Nouasseur facility exporting 40% of output to 11 African countries and France.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Specialty Pharmaceutical Distributors (HLAIAJAB), Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)

Keywords

• Pharmaceutical manufacturing
• Branded medications
• Cardiovascular treatments
• Oncology therapeutics
• Digital health applications

Headquarters

HQ city

Casablanca

HQ country

Morocco

HQ region

Africa

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Princeps (Brand-name) Pharmaceuticals: Revenue from proprietary brand-name medications developed by Servier, covering four therapeutic areas: oncology, cardio-metabolism, neurosciences, and immuno-inflammation. Represents 3.7 billion euros of the 4.9 billion euro group revenue in 2020/2021.
2. Generic Medications: Quality generic medications covering majority of pathologies to facilitate access to treatments for greater number of patients. Represents 1.2 billion euros of group revenue.
3. Pharmaceutical Manufacturing for Export: Manufacturing services for European laboratories including Biogaran, with 40% of production exported to 11 African countries and France.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

Servier Maroc markets and distributes a portfolio of branded pharmaceutical medications across four therapeutic areas (oncology, cardio-metabolism, neurosciences, and immuno-inflammation), and operates a GMP-certified manufacturing facility in Nouasseur producing dry dosage forms (tablets) for the Moroccan market with 40% of output exported to 11 African countries and France. The subsidiary also provides digital health applications for patients and healthcare professionals, including the Tension Diali (My BP Control) blood pressure monitoring app and the Servier Medical Art medical image database.

Product overview

Servier Maroc is a pharmaceutical company offering a portfolio of branded medications across four therapeutic areas (oncology, cardio-metabolism, neurosciences, and immuno-inflammation) along with digital health applications. The core offering consists of 23 pharmaceutical products including Bipreterax, Carivalan, Coralan, Cosyrel, Coveram, Coversyl, Daflon, Diamicron, Fludex LP, Hyperium, Liporosa, Lonsurf, Natrixam, ONIVYDE, Preterax, Stablon, Triplixam, Trivastal, Valdoxan, Vastarel, Viacoram, and Viacorlix. Complementing these are four digital health applications: Tension Diali (My BP Control) for hypertension management, Cardiological for physician education, Biblioclick Family for medical literature searches, and Servier Medical Art as a medical image resource. The products primarily target cardiovascular, metabolic, oncology, and neurological conditions.

Differentiator

Problem solved

Functional benefit

Brands

• Tension Diali (My BP Control): Mobile application for hypertensive patients in Morocco to monitor blood pressure, share data with physicians, and receive treatment reminders.
• Cardiological
• Biblioclick Family
• Servier Medical Art (SMART)

Quantifiable outcome

• 90% cure rate for colorectal cancer with early detection and treatment
• +3 more outcomes

Named customers3 records

Segments6 records

Ideal customer profiles3 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Agios PharmaceuticalscoreStrategic or Co-development Partner · 1 April 2021Servier acquired Agios Pharmaceuticals' oncology division for up to $2 billion, including TIBSOVO (ivosidenib), co-commercialization rights for IDHIFA with Bristol Myers Squibb, and a solid pipeline of phase 3 and early-stage oncology research projects. This acquisition strengthened Servier's commercial presence in the US hematology-oncology market.
• Bristol Myers SquibbminorChannel Partner/ Reseller/ Distributor · 1 April 2021Co-commercialization partnership for IDHIFA (enasidenib) in the United States, in addition to TIBSOVO acquired from Agios Pharmaceuticals.
• We4SheminorOthers · 8 March 2021Servier Maroc supports We4She gender equality charter including gender mix in recruitment, pay equity, management and executive committee gender mix, and board gender diversity.
• International Society of HypertensionminorStrategic or Co-development Partner · 1 October 2020Collaboration with International Society of Hypertension for the national public awareness campaign '#ParceQueJeTiensAToi' focused on importance of hypertension and diabetes diagnosis in Morocco.
• Association EMA-Maroc (Enfance Maghreb Avenir)minorOthers · 6 March 2020Servier Maroc announced support for EMA Association through financial and skills sponsorship. Commitment includes renovation of Bouzaniyine School for children in disadvantaged Casablanca neighborhoods, and support for Second Chance School in Nouaceur with educational activities, tutoring, and professional observation internships.
• Shire (acquired oncology division)coreStrategic or Co-development Partner · 16 April 2018Servier acquired Shire's oncology division for $2.4 billion, including ONCASPAR (pegaspargase) for leukemia, ONIVYDE (irinotecan) for pancreatic cancer, and two immuno-oncology development collaborations. This established Servier's direct commercial presence in the US market.
• Taiho PharmaceuticalcoreStrategic or Co-development Partner · 1 June 2015Exclusive licensing agreement for co-development and commercialization of LONSURF in Europe and other countries outside US, Canada, Mexico, and Asia. Taiho discovered and developed LONSURF (trifluridine/tipiracil combination).
• BiogaranminorChannel Partner/ Reseller/ DistributorServier Maroc produces medications on behalf of Biogaran for the European market, demonstrating manufacturing capabilities meeting European quality standards.

Scale indicators11 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• AstraZeneca Maroc: Moroccan arm of AstraZeneca, a global innovator pharma with strong cardiovascular, oncology, and respiratory franchises. Comparable to Servier Maroc in therapeutic focus (Coversyl-class hypertension franchise overlaps with AZ's cardiovascular portfolio) and field-sales-driven Moroccan go-to-market.
• Novartis Maroc: Local subsidiary of Novartis, a global innovator pharma group with strong cardiology and oncology presence. Comparable to Servier Maroc in therapeutic area overlap (cardio-metabolism, oncology) and go-to-market through medical reps and authorized pharmacies.
• MSD Maroc (Merck & Co.): Moroccan subsidiary of Merck & Co., a global innovator pharma. Comparable as a multinational selling patented oncology, cardiovascular, and metabolic drugs through Moroccan pharmacy channels with medical representative engagement.
• GlaxoSmithKline Maroc: Moroccan subsidiary of GSK, a global innovator pharma with vaccines, specialty, and primary care portfolios. Comparable to Servier Maroc in operating model (medical rep-driven sales, authorized pharmacy distribution) and therapeutic overlap in cardiovascular and metabolic disease.
• Roche Maroc: Moroccan operations of Roche, the world's largest oncology player. Closely comparable to Servier Maroc in oncology (Lonsurf, ONIVYDE overlap with Roche's portfolio) and specialty pharmaceutical distribution in Morocco.
• Sanofi Maroc: Moroccan subsidiary of Sanofi, another foundation-governed French pharmaceutical group. Directly comparable as a branded innovator pharma player serving the same Moroccan prescriber base across cardiovascular, diabetes, oncology, and rare disease with similar field-sales and pharmacy distribution model.
• Pfizer Maroc: Moroccan arm of Pfizer, one of the largest global pharma groups. Comparable as a multinational branded-innovator pharmaceutical manufacturer/distributor selling patented oncology, cardiovascular and metabolic products through authorized pharmacies in Morocco.

Emerging players

• Biogaran: France's leading generics manufacturer and Servier-owned entity, for which Servier Maroc already toll-manufactures product. Comparable because Biogaran and Servier Maroc operate on the same French/Maghreb manufacturing network, share GMP/FMD standards, and increasingly co-produce for European and African markets.

Regional players

• Sanofi Afrique Subsaharienne: Sanofi's sub-Saharan African distribution and manufacturing operations. Comparable to Servier Maroc's export activities covering 11 African countries and represents the same multinational-French-pharma-in-Africa competitive dynamic Servier Maroc faces for tenders and chronic-disease market share.
• Cooper Pharma (Maroc): Largest Moroccan-owned pharmaceutical manufacturer. Comparable to Servier Maroc as a Morocco-based pharma manufacturer with GMP-certified production, African export footprint, and branded/generic portfolio targeting similar prescribers — though focused primarily on the Moroccan and African markets rather than Europe.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/ServierMaroc
• LinkedInlinkedin.com/company/servier-maroc
• Instagraminstagram.com/servier_maroc

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Servier Maroc